As observed in cultures from OI patients and in cultures from healthy donors in the presence of the pro-osteoclastogenic cytokines, the treatment with 1 μmol/L neridronate determined a significant decrease in the CK-BB secretion compared with the control condition untreated with neridronate (p < 0.03). Here, CKB is linked to osteogenesis imperfecta.